1stOncology™: Cancer Intelligence Service – Page 15357 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 43rd Annual Health Care Conference

On May 2, 2018 Alkermes plc (NASDAQ: ALKS) reported that its corporate presentation will be webcast live at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 10:00 a.m. ET (3:00 p.m. BST) from Boston (Press release, Alkermes, MAY 2, 2018, View Source;p=RssLanding&cat=news&id=2346426 [SID1234525953]). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Contact:
Jennifer Zibuda
Corporate Communications
+1 781 609 6129

Aduro Biotech Reports First Quarter 2018 Financial Results

On May 2, 2018 Aduro Biotech, Inc. (NASDAQ:ADRO) reported financial results for the first quarter ended March 31, 2018. Net loss for the first quarter of 2018 was $21.5 million, or $0.28 per share, compared to net loss of $21.8 million, or $0.32 per share, for the same period in 2017 (Press release, Aduro Biotech, MAY 2, 2018, View Source;p=RssLanding&cat=news&id=2346437 [SID1234525952]).

Recent Developments:

Reported preclinical data on ADU-S100, BION-1301 and ADU-1604 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper)

Reported initial observations from the first patient treated with our personalized neoantigen-based immunotherapy

Received a milestone payment from Merck for initiation of a Phase 1 trial of our anti-CD27 antibody for patients with advanced solid tumors
Cash, cash equivalents and marketable securities totaled $327.8 million at March 31, 2018, compared to $349.7 million at December 31, 2017.

Revenue was $6.6 million for the first quarter of 2018 compared to $3.8 million for the same period in 2017. The increase of $2.8 million was primarily due to a $3.0 million milestone payment received from Merck for initiation of a Phase 1 trial for our anti-CD27 antibody.

Research and development expenses were $20.1 million for the first quarter of 2018 compared to $20.6 million for the same period in 2017. The decrease of $0.5 million was due to lower contract manufacturing expense of $3.1 million primarily related to BION-1301, partially offset by increases in clinical development and contract research expenses for our ongoing programs including ADU-S100, BION-1301, ADU-1604 and our personalized neoantigen-based immunotherapy, as well as increases in stock-based compensation and personnel related expenses.

General and administrative expenses were $9.0 million for the first quarter of 2018 compared to $8.3 million for the same period in 2017. The increase of $0.7 million was driven primarily by legal fees associated with our patent portfolio and higher stock-based compensation expense, partially offset by decreased compensation expense.

Income tax benefit was approximately $21 thousand for the first quarter of 2018 compared to an income tax benefit of $2.8 million for the same period in 2017. The income tax benefit for 2017 related to federal income tax benefit associated with the carryback of the 2017 losses.

Xencor to Present at Deutsche Bank 43rd Annual Health Care Conference

On May 2, 2018 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, reported that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 9:20 a.m. ET in Boston, MA (Press release, Xencor, MAY 2, 2018, View Source [SID1234525946]).

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company’s website located at www.xencor.com. A replay of the presentation will be posted on the Xencor website approximately one hour after the live event and will be available for 90 days following the presentation.

Selecta Biosciences Announces Date of First Quarter 2018 Financial Results Conference Call

On May 2, 2018 Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immunogenicity, reported that it plans to issue its first quarter 2018 financial results before the open of the U.S. financial markets on Wednesday, May 09, 2018 (Press release, Selecta Biosciences, MAY 2, 2018, View Source [SID1234525945]).

At 8:30 a.m. ET that day, Selecta will host a conference call via live webcast to discuss these results and provide a corporate update. Investors and the public can access a live and archived webcast of this call via the Investors & Media section of the company’s website, View Source Individuals may also participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10118841

PDL BioPharma to Announce First Quarter 2018 Financial Results on May 9, 2018

On May 2, 2018 PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) reported that it will release its first quarter 2018 financial results for the period ended March 31, 2018, on Wednesday, May 9, 2018, after market close (Press release, PDL BioPharma, MAY 2, 2018, View Source [SID1234525944]). PDL’s management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.

Conference Call Details
To access the live conference call via phone, please dial (800) 668-4132 from the United States and Canada or (224) 357-2196 internationally. The conference ID is 1798597. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 1798597.

To access the live and subsequently archived webcast of the conference call, go to the Company’s website at View Source and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.